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Rift Valley Fever  
in Kedougou,  
Southeastern  
Senegal, 2012
To the Editor: Rift Valley fever 
(RVF) is an acute, febrile, viral dis-
ease caused by Rift Valley fever virus 
(RVFV), a phlebovirus of the family 
Bunyaviridae that is endemic to sub-
Saharan Africa. RVF mortality and 
abortion rates among young domesti-
cated ruminants and pregnant females 
are high.
In humans, clinical manifesta-
tions range from mild to severe syn-
dromes, which can include neurologic, 
hemorrhagic, and hepatic features and 
retinitis, and which sometimes result 
in death (1). Diagnosis of RVF is chal-
lenging for clinicians because clinical 
manifestations are not specific (2). 
Heavy rainfall and flooding create con-
ditions for emergence of RVF vectors 
(Aedes and Culex spp.  mosquitoes), 
and dispersion of this disease into new 
areas is linked to migration of infected 
livestock, wildlife, or mosquitoes.
Since 1987, when the Diama dam 
was built, RVF outbreaks in Maurita-
nia have been reported regularly (3). 
In Kedougou, southeastern Senegal, 
RVFV was isolated 4 times from Ae. 
dalzieli mosquitoes and once from a 
person with a mild case of RVF (4). We 
report results of a field investigation 
and laboratory findings for a human 
case of RVF detected by surveillance 
of acute febrile illnesses in Kedougou.
On October 16, 2012, a 27-year-
old man (school teacher) who lived and 
worked in Baya village in the Kedou-
gou region of Senegal (12°27′50″N, 
12°28′6″W) visited the Kedougou 
military health post because of high 
fever, chills, headache, back pain, 
myalgia, and arthralgia that started on 
October 14. He reported regular con-
tact with domesticated animals (cows, 
sheep, and goats) during farming.
A thick blood smear for the pa-
tient showed a positive result for 
malaria, and specific treatment was 
given. As part of surveillance for 
acute febrile illnesses, blood samples 
from the patient were tested for IgM 
against RVF, chikungunya, dengue, 
West Nile, yellow fever, Zika, and 
Crimean-Congo hemorrhagic fever 
viruses; and for viral RNA and virus 
(5,6). All test results for IgM against 
the 7 viruses were negative 
RVFV was isolated from newborn 
mice that were intracerebrally inocu-
lated with a blood sample from the pa-
tient. Viral RNA was detected by re-
verse transcription PCR in serum from 
the patient. Phylogenetic analysis of 
the partial nonstructural protein gene 
on the small RNA segment showed 
that the RVFV isolate was closely re-
lated to a strain that had circulated in 
Mauritania in 2012 (Figure).
An epidemiologic field investiga-
tion was conducted to assess the extent 
of RVFV circulation. During this in-
vestigation, the case-patient provided 
an additional blood sample. In addi-
tion, 115 contacts of the case-patient, 
including primary school students, 
friends, family members and neigh-
bors (median age 12 years, range 6–75 
years; female:male sex ratio 1.6) were 
also sampled and questioned to iden-
tify asymptomatic and benign cases. A 
total of 218 samples from patients at-
tending the nearest health posts in Ibel 
and Thiokoye villages during October 
2012 were also tested during surveil-
lance of acute febrile illnesses.
All 334 samples were nega-
tive for RVFV RNA and IgM and 
IgG against RVFV except for sam-
ples from 3 patients, including the 
case-patient, which were positive 
for RVFV-specific IgG and malaria 
parasites. The 2 other patients were a 
32-year-old tradesman and a 20-year-
old housewife sampled during sur-
veillance of acute febrile illnesses in 
Kedougou and Bandafassi, which is 
30 km from Baya (online Technical 
Appendix Figure, wwwnc.cdc.gov/
EID/article/20/3/13-1174-Techapp1.
pdf). No RVFV RNA was detected 
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from 519 mosquito pools sampled in 
the Kedougou region during October 
2012, although these pools included 
7 species previously found associated 
with RVFV and which represented 
26.6 % of the pools.
The patient reported no travel 
outside Kedougou in the 2-year pe-
riod before his illness. Because no 
evidence of recent RVFV circulation 
among humans and mosquitoes was 
found, we believe that the patient was 
infected by contact with an animal 
imported from Mauritania. This hy-
pothesis is based on reports by farm-
ers from neighboring villages (Baya, 
Ibel, Thiokoye, and Dondol) of the 
presence of ruminants imported from 
Mauritania in the market in Thiokoye 
village and of deaths and abortions 
among sheep and goats in their villag-
es during October–November 2012. 
However, no animals were sampled 
during the investigation.
There is an abundance of compe-
tent vectors for RVFV in Kedougou 
(4). In addition, there are massive hu-
man migrations resulting from gold 
mining and regular importation of 
animals from RVF-endemic regions 
of western Africa. Thus, an integrated 
human and animal surveillance system 
should be implemented or reinforced 
to avoid large-scale RVF outbreaks 
in Kedougou.
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Concomitant  
Multidrug-Resistant 
Pulmonary  
Tuberculosis  
and Susceptible  
Tuberculous  
Meningitis
To the Editor: In 2012, a 
34-year-old HIV-seronegative man 
was hospitalized after several months 
of cough, fever, night sweats, 10-kg 
weight loss, and, in the past month, 
severe headache. The patient was 
born in Romania and had lived in 
France for 2 years. He had a history 
of pulmonary tuberculosis (TB) for 
which treatment was started in Roma-
nia in 2006 and 2008, but he did not 
complete treatment. The treatment he 
received in Romania was unknown.
At hospital admission, the patient 
had a fever of 39°C, stiff neck, and 
swollen cervical and axillary lymph 
nodes. A chest radiograph showed 
multiple cavities and nodular opaci-
ties in both superior lobes. Sputum 
auramine staining indicated that 
acid-fast bacilli was positive, which 
supported the diagnosis of pulmonary 
TB. Examination of cerebrospinal 
fluid (CSF) revealed hypoglycorra-
chia (0.95 mmol/L, concentration ra-
tio CSF/blood: 0.2 [reference range 
0.5–0.75]), hyperproteinorrachia (1.3 
g/L [reference range 0.2–0.4 g/L]), 
erythrocyte count 2,000 μL (reference 
value <10 μL), and leukocyte count 
150 μL (reference value <10 μL). Au-
ramine staining showed no acid-fast 
bacilli in CSF. Standard antituber-
culous therapy with rifampin (RIF), 
isoniazid (INH), pyrazinamide, and 
ethambutol was started.
Genomic amplification–based 
assay (Xpert MTB/RIF; Cepheid, 
Maurens-Scopont, France), performed 
on sputum, confirmed the presence of 
the Mycobacterium tuberculosis ge-
nome and detected resistance to RIF 
(Table). The line probe assay Geno-
type MTBDRplus (Hain Lifescience, 
Bandol, France) performed on sputum 
showed a positive signal for all wild-
type sequences and for rpoB (S531L 
associated with RIF resistance) and 
katG (S315T associated with INH 
resistance) mutations, suggesting the 
presence of mixed susceptible and 
resistant M. tuberculosis. Second-line 
treatment was started: moxifloxa-
cin, amikacin, ethionamide, para-
aminosalicylic acid, cycloserine and 
linezolid. The presence of mixed M. 
tuberculosis organisms in lungs was 
confirmed with culture methods and 
by phenotypic drug susceptibility test-
ing (DST) that showed 1% resistant 
mutant to RIF and INH (proportion 
method) (1). The isolate was consid-
ered resistant to RIF and INH and was 
thus categorized as multidrug resistant 
(MDR). DST also showed that the 
sputum isolate had an elevated pro-
portion of ofloxacin-resistant mutants 
(2 mg/L, 0.02% resistant mutants). 
Although no mutation in gyrA or gyrB 
was detected on colonies grown in the 
absence of fluoroquinolone, a gyrB 
N538D mutation was identified on 
colonies grown on ofloxacin medium. 
On the basis of the DST results, the 
treatment was changed to ethambutol, 
pyrazinamide, amikacin, moxifloxa-
cin, para-aminosalicylic acid, and li-
nezolid. CSF culture was eventually 
positive for M. tuberculosis on Low-
enstein-Jensen medium after 30 days. 
DST performed on the CSF isolate 
showed a drug-sensitive phenotype; 
thus, RIF was reintroduced in addition 
to the other antimicrobial drugs. After 
3 months, although the patient had 
improved, he left the hospital against 
medical advice without providing fol-
low-up contact information.
Mycobacterial interspersed re-
petitive unit–variable number tandem 
repeat (MIRU-VNTR) analysis was 
conducted on culture of the sputum 
and CSF sample and on colonies 
grown on INH, RIF, and ofloxacin–
containing medium, as described (2) 
(Table). This analysis showed dif-
ferent genotypes for the lung MDR 
and the CSF-susceptible isolates. 
None of the MIRU-VNTR patterns 
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Table.	Localization,	drug-susceptibility	results,	and	MIRU-VNTR	genotypes	of	Mycobacterium tuberculosis strains	recovered	from	a	
man	with	both	pulmonary	tuberculosis	and	tuberculous	meningitis,	France,	2012* 
Tissue MIRU-VNTR	genotype	1	
222213222234225153333622 
MIRU-VNTR	genotype	2	
224243122234225143335622 
Lung Isoniazid	and	rifampin	resistant,	fluoroquinolone	
susceptible,	rpoB S531L,	katG S315T,	no	mutations	
in gyrA and	gyrB 
Pan-susceptible	except	to	fluoroquinolones,	no	
mutations in rpoB,	katG, and	gyrA;	gyrB N538D 
Cerebrospinal	fluid  Pan-susceptible,	no	mutations	in	rpoB,	katG,	gyrA,	
and	gyrB 
*MIRU-VNTR,	mycobacterial	interspersed	repetitive	unit–variable	number	tandem	repeat. 
 
